| Autor: |
Sheila Bermejo, Carles Oriol GarcÃa, Eva RodrÃguez, Clara Barrios, Sol Otero, Sergi Mojal, Julio Pascual, MarÃa José Soler |
| Jazyk: |
angličtina |
| Rok vydání: |
2018 |
| Předmět: |
|
| Zdroj: |
Nefrología (English Edition), Vol 38, Iss 2, Pp 197-206 (2018) |
| Druh dokumentu: |
article |
| ISSN: |
2013-2514 |
| DOI: |
10.1016/j.nefroe.2017.12.002 |
| Popis: |
Background and objectives: Diabetic kidney disease is the leading cause of end-stage chronic kidney disease (CKD). The reninâangiotensinâaldosterone system (RAAS) blockade has been shown to slow the progression of diabetic kidney disease. Our objectives were: to study the percentage of patients with diabetic kidney disease treated with RAAS blockade, to determine its renal function, safety profile and assess whether its administration is associated with increased progression of CKD after 3 years of follow-up. Materials and methods: Retrospective study. 197 diabetic kidney disease patients were included and divided into three groups according to the treatment: patients who had never received RAAS blockade (non-RAAS blockade), patients who at some point had received RAAS blockade (inconstant-RAAS blockade) and patients who received RAAS blockade (constant-RAAS blockade). Clinical characteristics and analytical variables such as renal function, electrolytes, glycosylated hemoglobin and glomerular filtration rate according to CKD-EPI and MDRD formulas were assessed. We also studied their clinical course (baseline, 1 and 3 years follow-up) in terms of treatment group, survival, risk factors and renal prognosis. Results: Non-RAAS blockade patients had worse renal function and older age (p |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
